18. Spinocerebellar degeneration Clinical trials / Disease details
Clinical trials : 76 / Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04817111 (ClinicalTrials.gov) | May 17, 2021 | 10/3/2021 | NAD+ Precursor Supplementation in Friedreich's Ataxia | A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia | Friedreich Ataxia | Drug: MIB-626 | Metro International Biotech, LLC | Children's Hospital of Philadelphia | Active, not recruiting | 18 Years | 64 Years | All | 10 | Phase 2 | United States |